Market Place
Sourcing Support
Adagene Showcases Muzastotug`s Role at AACR 2026
17 Apr 2026 //
FIRSTWORD PHARMA
Adagene Unveils 2025 Financials, Corporate Update
01 Apr 2026 //
GLOBENEWSWIRE
Adagene To Showcase Muzastotug (ADG126) At 2026 (AACR) Meeting
17 Mar 2026 //
GLOBENEWSWIRE
Adagene To Participate In Two Upcoming Investor Conferences
17 Feb 2026 //
GLOBENEWSWIRE
Adagene Provides Business Update And 2026 Objectives
23 Jan 2026 //
GLOBENEWSWIRE
Adagene Reveals FDA Fast Track For Muzastotug In Cancer
16 Dec 2025 //
GLOBENEWSWIRE
Third Arc Bio teams up with Adagene to create T-cell engagers
13 Nov 2025 //
GLOBENEWSWIRE
Adagene Doses First Patient in Ph2 Muzastotug Combo Study
31 Oct 2025 //
GLOBENEWSWIRE
Adagene Expands SAFEbody Collab, License With Exelixis For 3 ADC
16 Sep 2025 //
GLOBENEWSWIRE
Adagene`s ADG126 Highlighted in Two Presentations at 2025 CSCO
05 Sep 2025 //
GLOBENEWSWIRE
Adagene to Participate in Two Investor Conferences in September
26 Aug 2025 //
GLOBENEWSWIRE
Adagene`s Six-Month 2025 Financial Results and Corporate Updates
12 Aug 2025 //
GLOBENEWSWIRE
Adagene, ConjugateBio Collaborate on New Antibody Drug Conjugate
08 Jul 2025 //
GLOBENEWSWIRE
Adagene Shows Ph1b/2 Data For ADG126 Combo In Colorectal Cancer
22 May 2025 //
GLOBENEWSWIRE
Adagene to Present at 11th Annual Immuno-Oncology 360° Summit
13 Mar 2025 //
GLOBENEWSWIRE
Adagene Starts Investigator-Led Ph 2 Trial of Muzastotug
27 Feb 2025 //
GLOBENEWSWIRE
Adagene Updates Muzastotug, Keytruda Data In Colorectal Cancer
27 Jan 2025 //
GLOBENEWSWIRE
Adagene To Present Muzastotug Data With Keytruda At GI Symposium
21 Jan 2025 //
GLOBENEWSWIRE
Adagene Presents Data on Anti-CTLA-4 SAFEbody® ADG126 at SITC
07 Nov 2024 //
GLOBENEWSWIRE
Adagene Announces Poster Presentations On ADG126 At SITC
09 Oct 2024 //
GLOBENEWSWIRE
Adagene Presents ADG126 Combo Data At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
Adagene to Participate in Investor Conferences in September
29 Aug 2024 //
GLOBENEWSWIRE
Adagene To Present ADG126-Pembrolizumab Combo Data At ESMO Congress
12 Jul 2024 //
GLOBENEWSWIRE
Adagene Announces Progress and Expansion of Collaboration Program for Masked
09 Feb 2024 //
GLOBENEWSWIRE
Adagene Presents Results Reinforcing Best-in-Class Profile of ADG126
16 Jan 2024 //
GLOBENEWSWIRE
Adagene To Present Results of anti-CTLA-4 SAFEbody ADG126 with Pembrolizumab
04 Jan 2024 //
GLOBENEWSWIRE
Adagene Presents Data Demonstrating Best-in-Class Therapeutic Index for ADG126
03 Nov 2023 //
GLOBENEWSWIRE
Adagene Announces Presentation on Optimal Dose Selection for ADG126
12 Oct 2023 //
GLOBENEWSWIRE
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing
18 Apr 2023 //
GLOBENEWSWIRE
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody, ADG126
14 Mar 2023 //
GLOBENEWSWIRE
Adagene Announces Data Demonstrating Safety of Anti-CTLA-4 SAFEbody ADG126
09 Jan 2023 //
GLOBENEWSWIRE
